Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Our licensing partner Verrica Pharmaceuticals today announced that the first patient has been dosed in Part 2 of their Phase II study evaluating our lead compound, LTX-315 - by Verrica... | April 12, 2023
Accepted abstracts include three summarizing findings from separate, large-scale, real-world studies evaluating clinical utility of Decipher Prostate Genomic Classifier ... | April 12, 2023
By Kirk Maltais --Corn for May delivery rose 0.8%, to $6.56 a bushel, on the Chicago Board of Trade on Wednesday, with traders evaluating supplies as tight even though the USDA didn't cut its... | April 12, 2023
BELLUS Health Inc. announced positive data from its Phase 1 bioavailability equivalence study evaluating a once-daily Extended-Release formulation of camlipixant in comparison to a twice-daily... | April 6, 2023
Continued advancement of global patient enrollment with approvals and site activations in the U.S., Switzerland, France, Spain and ItalyEnrollment continuing to progress toward an interim analysis expected